The group is recognized for the rapid development of a SARS-CoV-2 Research Grade Test Material, RGTM 10169, to assess RNA-based diagnostic tests and benchmark SARS-CoV-2 test control materials. In response to the COVID-19 pandemic, the RGTM was designed, produced and shipped to stakeholders within 90 days from project inception. The material is highly characterized RNA fragments that contain sequences from the SARS-CoV-2 genome. Over 200 units were provided to domestic (84) and international (52) stakeholders, including diagnostic laboratories, developers of tests, and metrology institutes.